Fig. 5.

AURKA or AURKB targeting decreases the transformed phenotype of lung cells in a KRAS-dependent manner. Primary immortalized human airway cells (SALEB) and their KRAS-transformed counterpart (SAKRAS) were treated with 0.1 % DMSO (DMSO) or 1uM AI II (AI II) as indicated. H1703-TrexB and H1703-G12V lung cancer cells were also treated with 0.1 % DMSO (DMSO) or 1 μM AI II (AI II) as indicated. To induce KRAS expression H1703-TrexB and H1703-G12V cells were simultaneously treated with 2 μg/mL doxycycline (DOX + DMSO or DOX + AI II) where indicated. a Growth curve analysis of cells. All drug treatments (DMSO, AI II, DOX + DMSO, DOX + AI II) were continued for 12 days. b Cells were plated for clonogenic assays as described in methods and treated for 21 days as indicated. Colonies formed were stained with crystal violet and counted. Images shown are representative of three independent experiments. c Anchorage-independent growth was evaluated by plating the indicated cells in soft agar as described in methods. Cells were then treated for 21 days as indicated. Colonies formed were stained with MTT and counted. Images shown are representative of three independent experiments. In all cases, statistical significance was determined when appropriate by Student’s t-test (*p < 0.05, **p < 0.01) and the groups being compared are indicated by horizontal bars